C&D Emerging Industry Equity Investment

C&D Emerging Industry Equity Investment is a professional equity asset management institution under C&D Group, a large-scale comprehensive investment holding group. The firm specializes in emerging industries such as healthcare, advanced manufacturing, and TMT/consumption. Its mission is to create new value and empower emerging enterprises to achieve stronger development. The company has a registered capital of RMB 2 billion and manages over RMB 21.5 billion in funds. It has co-established more than 100 investment funds with various institutions.

The firm's investment strategy targets sectors including healthcare, advanced manufacturing, and TMT/consumption. Within healthcare, it focuses on biopharmaceuticals, medical devices, pharmaceutical industry chains, and medical services. In advanced manufacturing, it invests in new energy, semiconductors, intelligent manufacturing, and key materials. The TMT/consumption sector includes logistics, supply chain, consumption, and digital technology. C&D Emerging Industry Equity Investment engages in early-stage, growth, late-stage, and pre-IPO investments, primarily within China.

C&D Emerging Industry Equity Investment has been recognized for its performance and contributions to the industry. In 2023, it was ranked among the 'Top 50 Chinese State-owned Investment Institutions' by Zero2IPO. In 2022, it received multiple awards at the CVAwards, including 'Top 30 Best Limited Partners in China for 2022' and 'Top 50 Best Corporate Venture Capital in China for 2022'. These accolades reflect the firm's commitment to supporting emerging enterprises and contributing to the development of China's capital market.